Galera Therapeutics (GRTX) Competitors

$0.09 0.00 (-1.80%)

As of 03:18 PM Eastern

GRTX vs. BGM, SNTI, DARE, PLRZ, and TVRD

Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include BGM Group (BGM), Senti Biosciences (SNTI), Dare Bioscience (DARE), Polyrizon (PLRZ), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry.

How does Galera Therapeutics compare to BGM Group?

BGM Group (NASDAQ:BGM) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Galera Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 50.8% of Galera Therapeutics shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: BGM Group has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.64, suggesting that its stock price is 164% more volatile than the S&P 500.
: BGM Group has higher revenue and earnings than Galera Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BGM Group $25.10M 1.14 -$1.44M N/A N/A
Galera Therapeutics N/A N/A -$59.08M $0.64 0.14
: Company Net Margins Return on Equity Return on Assets
BGM Group N/A N/A N/A
Galera Therapeutics N/A N/A -99.34%
: In the previous week, BGM Group's average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score.
Company Overall Sentiment
BGM Group Neutral
Galera Therapeutics Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.14	-$1.44M	N/A	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Galera Therapeutics	N/A	N/A	-99.34%

Company	Overall Sentiment
BGM Group	Neutral
Galera Therapeutics	Neutral

Summary

BGM Group beats Galera Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Galera Therapeutics compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

: In the previous week, Senti Biosciences had 1 more articles in the media than Galera Therapeutics. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Galera Therapeutics. Senti Biosciences' average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score.
Company Overall Sentiment
Senti Biosciences Neutral
Galera Therapeutics Neutral
: Senti Biosciences has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.64, suggesting that its stock price is 164% more volatile than the S&P 500.
: Senti Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 790.99%. Given Senti Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Senti Biosciences is more favorable than Galera Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senti Biosciences
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
Galera Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Galera Therapeutics has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Senti Biosciences $20K 1,485.38 -$61.44M -$3.19 N/A
Galera Therapeutics N/A N/A -$59.08M $0.64 0.14
: 25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Galera Therapeutics' return on equity of 0.00% beat Senti Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Senti Biosciences N/A -301.48% -90.03%
Galera Therapeutics N/A N/A -99.34%

Company	Overall Sentiment
Senti Biosciences	Neutral
Galera Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,485.38	-$61.44M	-$3.19	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-301.48%	-90.03%
Galera Therapeutics	N/A	N/A	-99.34%

Summary

Senti Biosciences and Galera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Galera Therapeutics compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

: In the previous week, Dare Bioscience's average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score.
Company Overall Sentiment
Dare Bioscience Neutral
Galera Therapeutics Neutral
: Dare Bioscience has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500.
: Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 205.81%. Given Dare Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Dare Bioscience is more favorable than Galera Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dare Bioscience
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
Galera Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Dare Bioscience has higher revenue and earnings than Galera Therapeutics. Dare Bioscience is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dare Bioscience $1.03M 46.22 -$13.40M -$1.25 N/A
Galera Therapeutics N/A N/A -$59.08M $0.64 0.14
: 6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 4.8% of Dare Bioscience shares are owned by insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Company Net Margins Return on Equity Return on Assets
Dare Bioscience N/A N/A -56.52%
Galera Therapeutics N/A N/A -99.34%

Company	Overall Sentiment
Dare Bioscience	Neutral
Galera Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	46.22	-$13.40M	-$1.25	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-56.52%
Galera Therapeutics	N/A	N/A	-99.34%

Summary

Dare Bioscience beats Galera Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Galera Therapeutics compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Polyrizon N/A N/A -$3.34M N/A N/A
Galera Therapeutics N/A N/A -$59.08M $0.64 0.14
: Polyrizon has a beta of -2.04, meaning that its share price is 304% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500.
: Company Net Margins Return on Equity Return on Assets
Polyrizon N/A N/A N/A
Galera Therapeutics N/A N/A -99.34%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polyrizon
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Galera Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Polyrizon had 4 more articles in the media than Galera Therapeutics. MarketBeat recorded 4 mentions for Polyrizon and 0 mentions for Galera Therapeutics. Polyrizon's average media sentiment score of 0.18 beat Galera Therapeutics' score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.
Company Overall Sentiment
Polyrizon Neutral
Galera Therapeutics Neutral
: 50.8% of Galera Therapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Galera Therapeutics	N/A	N/A	-99.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Polyrizon	Neutral
Galera Therapeutics	Neutral

Summary

Polyrizon beats Galera Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Galera Therapeutics compare to Tvardi Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

: Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Galera Therapeutics N/A N/A -$59.08M $0.64 0.14
Tvardi Therapeutics N/A N/A -$18.21M -$5.59 N/A
: Galera Therapeutics has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.
: Galera Therapeutics' return on equity of 0.00% beat Tvardi Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Galera Therapeutics N/A N/A -99.34%
Tvardi Therapeutics N/A -73.53% -35.22%
: Tvardi Therapeutics has a consensus price target of $55.50, indicating a potential upside of 1,404.07%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Galera Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Tvardi Therapeutics
1 Sell rating(s)

3 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.50
: In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Tvardi Therapeutics'average media sentiment score.
Company Overall Sentiment
Galera Therapeutics Neutral
Tvardi Therapeutics Neutral
: 50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$5.59	N/A

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Tvardi Therapeutics	N/A	-73.53%	-35.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Company	Overall Sentiment
Galera Therapeutics	Neutral
Tvardi Therapeutics	Neutral

Summary

Galera Therapeutics and Tvardi Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRTX vs. The Competition

Export

Metric	Galera Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.98M	$889.47M	$6.25B	$11.87B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	-0.26	1.71	29.04	28.47
Price / Sales	N/A	120.50	476.61	60.92
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	-0.04	7.60	9.67	6.67
Net Income	-$59.08M	-$4.80M	$3.55B	$332.53M
7 Day Performance	N/A	-0.05%	1.70%	2.01%
1 Month Performance	N/A	5.50%	5.62%	9.19%
1 Year Performance	N/A	30.96%	34.41%	39.59%

Galera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRTX Galera Therapeutics	N/A	$0.09 -1.8%	N/A	N/A	$6.98M	N/A	N/A	30	Upcoming Earnings Gap Down
BGM BGM Group	0.7014 of 5 stars	$0.31 +3.3%	N/A	N/A	$30.14M	$26.85M	N/A	298	Gap Down
SNTI Senti Biosciences	2.5988 of 5 stars	$0.96 -2.0%	$8.50 +781.7%	N/A	$30.02M	$20K	N/A	4
DARE Dare Bioscience	2.0579 of 5 stars	$2.06 -1.9%	$10.00 +385.2%	N/A	$30.01M	$1.03M	N/A	30	Upcoming Earnings Gap Up
PLRZ Polyrizon	0.316 of 5 stars	$16.16 +2.8%	N/A	N/A	$29.39M	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRTX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galera Therapeutics (GRTX) Competitors

GRTX vs. BGM, SNTI, DARE, PLRZ, and TVRD

How does Galera Therapeutics compare to BGM Group?

Summary

How does Galera Therapeutics compare to Senti Biosciences?

Summary

How does Galera Therapeutics compare to Dare Bioscience?

Summary

How does Galera Therapeutics compare to Polyrizon?

Summary

How does Galera Therapeutics compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTX vs. The Competition

Galera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galera Therapeutics (GRTX) Competitors

GRTX vs. BGM, SNTI, DARE, PLRZ, and TVRD

How does Galera Therapeutics compare to BGM Group?

Summary

How does Galera Therapeutics compare to Senti Biosciences?

Summary

How does Galera Therapeutics compare to Dare Bioscience?

Summary

How does Galera Therapeutics compare to Polyrizon?

Summary

How does Galera Therapeutics compare to Tvardi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTX vs. The Competition

Galera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools